Last reviewed · How we verify
CCK (Kinevac)
CCK (Kinevac) is a CCK receptor agonist Small molecule drug developed by GlaxoSmithKline. It is currently FDA-approved for Diagnostic agent for assessment of gallbladder function and biliary dyskinesia, Stimulation of pancreatic secretion for diagnostic pancreatic function testing.
CCK (cholecystokinin) is a synthetic peptide hormone that binds to CCK receptors to stimulate gallbladder contraction and pancreatic secretion.
CCK (cholecystokinin) is a synthetic peptide hormone that binds to CCK receptors to stimulate gallbladder contraction and pancreatic secretion. Used for Diagnostic agent for assessment of gallbladder function and biliary dyskinesia, Stimulation of pancreatic secretion for diagnostic pancreatic function testing.
At a glance
| Generic name | CCK (Kinevac) |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | CCK receptor agonist |
| Target | CCK-A receptor |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology / Diagnostic |
| Phase | FDA-approved |
Mechanism of action
Kinevac is a synthetic form of cholecystokinin, a naturally occurring hormone that acts on CCK-A receptors located on gallbladder smooth muscle and pancreatic acinar cells. When administered intravenously, it mimics the physiological effects of endogenous CCK, causing gallbladder contraction and promoting pancreatic enzyme secretion. This mechanism makes it useful as a diagnostic agent to assess gallbladder function and pancreatic response.
Approved indications
- Diagnostic agent for assessment of gallbladder function and biliary dyskinesia
- Stimulation of pancreatic secretion for diagnostic pancreatic function testing
Common side effects
- Abdominal pain or cramping
- Nausea
- Dizziness
- Flushing
Key clinical trials
- POTS-FLOW: Interplay Between Gut Hormones and Autonomic Postprandial Blood Flow Regulation in Patients With POTS (NA)
- Study to Assess the Way the Body Absorbs, Distributes, Breaks Down and Eliminates Radioactive BMS-986278 in Healthy Male Participants (PHASE1)
- Thyroid Hormones Homeostasis and Energy Metabolism Changes During Stimulation of Endogenously Secreted Bile Acids (BAs) (PHASE3)
- A Study Evaluating the Effect of Albiglutide on Gallbladder Emptying in Healthy Subjects (PHASE4)
- Dose Response of Intravenous Sincalide(CCK-8) for Gallbladder Emptying (NA)
- The Impact of Gall Bladder Emptying and Bile Acids on the Human GLP-1-secretion (NA)
- Sincalide (Cholecystokinin Octapeptide) Versus Placebo in Neonates at High Risk for Developing Parenteral Nutrition Associated Cholestasis (NA)
- Ultrasound for Diagnosis of Biliary Dyskinesia (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CCK (Kinevac) CI brief — competitive landscape report
- CCK (Kinevac) updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI
Frequently asked questions about CCK (Kinevac)
What is CCK (Kinevac)?
How does CCK (Kinevac) work?
What is CCK (Kinevac) used for?
Who makes CCK (Kinevac)?
What drug class is CCK (Kinevac) in?
What development phase is CCK (Kinevac) in?
What are the side effects of CCK (Kinevac)?
What does CCK (Kinevac) target?
Related
- Drug class: All CCK receptor agonist drugs
- Target: All drugs targeting CCK-A receptor
- Manufacturer: GlaxoSmithKline — full pipeline
- Therapeutic area: All drugs in Gastroenterology / Diagnostic
- Indication: Drugs for Diagnostic agent for assessment of gallbladder function and biliary dyskinesia
- Indication: Drugs for Stimulation of pancreatic secretion for diagnostic pancreatic function testing
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing